| 1404 |
National Cancer Institute |
Html |
en |
Sleep Disorders (PDQ®)–Patient Version |
Expert-reviewed information summary about causes and management of sleep disorders in people with cancer. |
| normal sleep patterns | 0.734479 |
| Relaxation therapy | 0.493159 |
| moderate sleep disorders | 0.656166 |
| sleeping problems | 0.484122 |
| PDQ cancer information | 0.646663 |
| sleep medicines | 0.601935 |
| health care team | 0.479673 |
| clinical trials | 0.518721 |
| sleep history | 0.612308 |
| sleep apnea | 0.593611 |
| cancer patient sleeps | 0.499804 |
| cancer information summary | 0.579061 |
| clinical trial | 0.483994 |
| breast cancer prevention | 0.483786 |
| good sleep habits | 0.703452 |
| cancer patients | 0.541537 |
| treatment instructions | 0.483188 |
| sleep problems | 0.627478 |
| mild sleep disorders | 0.656367 |
| NCI’s PDQ | 0.480637 |
| NCI PDQ cancer | 0.525102 |
| Common cancer treatments | 0.495476 |
| sleep disorder clinic | 0.627008 |
| deep sleep | 0.635758 |
|
| treatment | 0.54776 |
| cancer prevention | 0.48441 |
| lighter sleep | 0.598128 |
| Cancer Information Service | 0.493437 |
| REM sleep | 0.662129 |
| sleep | 0.949433 |
| good night | 0.507447 |
| National Cancer Institute | 0.585654 |
| sleep repeat | 0.634943 |
| light sleep | 0.635787 |
| Palliative Care Editorial | 0.524141 |
| new treatment | 0.481731 |
| sleep disorders | 0.849206 |
| sleep restriction | 0.605553 |
| Cancer Care page | 0.486706 |
| Care Editorial Board | 0.525467 |
| health | 0.498616 |
| PDQ summary | 0.533115 |
| sleep disorder | 0.712776 |
| sleep problem | 0.601447 |
| cancer information summaries | 0.498019 |
| comprehensive cancer information | 0.497854 |
| cancer | 0.67715 |
| stimulus control | 0.540953 |
|
CLICK HERE |
| 1653 |
National Cancer Institute |
Html |
en |
Cancer Genetics Overview (PDQ®)–Health Professional Version |
Expert-reviewed information summary in which the features of hereditary cancer and the structure and content of other PDQ cancer genetics summaries are described. The summary also contains an extensive list of genetics resources available online. |
| risk assessment | 0.737084 |
| germline genetic testing | 0.616915 |
| pathogenic germline variants | 0.607786 |
| genetics cancer risk | 0.586595 |
| germline testing | 0.54014 |
| individual PDQ summaries | 0.545357 |
| common genetic variants | 0.594544 |
| Founder pathogenic variants | 0.555775 |
| Cancer Genetics Risk | 0.634713 |
| tumor sequencing | 0.540563 |
| cancer risk counseling | 0.587676 |
| genetic risk | 0.584149 |
| health care providers | 0.553143 |
| genetic risk assessment | 0.574763 |
| family members | 0.586643 |
| pathogenic variant | 0.712171 |
| cancer predisposition genes | 0.581734 |
| cancer risk assessment | 0.656292 |
| BRCA1/BRCA2 pathogenic variants | 0.580746 |
| rare genetic variants | 0.585466 |
| familial cancer risk | 0.606217 |
| germline pathogenic variant | 0.590911 |
| specific pathogenic variant | 0.581389 |
| genetic cancer susceptibility | 0.617626 |
| genetic sequence testing | 0.55336 |
|
| breast cancer panel | 0.575181 |
| genetic counseling | 0.75599 |
| certain pathogenic variants | 0.569596 |
| cancer susceptibility genes | 0.662603 |
| multigene testing | 0.554102 |
| pathogenic variants | 0.772898 |
| term pathogenic variant | 0.577821 |
| genetic information | 0.615701 |
| predisposition genetic testing | 0.569525 |
| health care | 0.629277 |
| actionable genetic variants | 0.56222 |
| cancer susceptibility | 0.729483 |
| multigene tests | 0.585492 |
| Cancer genetic counseling | 0.65952 |
| breast cancer | 0.623534 |
| cancer predisposition multigene | 0.547293 |
| cancer susceptibility gene | 0.552935 |
| well-characterized cancer susceptibility | 0.539905 |
| genetic variants | 0.628939 |
| prostate cancer | 0.563348 |
| genetic testing | 0.723596 |
| family history | 0.559221 |
| cancer risk | 0.746235 |
| cancer | 0.908258 |
|
CLICK HERE |
| 1908 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia mieloide aguda en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda en adultos. |
| linfocÃtica aguda | 0.505572 |
| leucemia promielocÃtica aguda | 0.536157 |
| siguientes procedimientos | 0.505247 |
| células madre | 0.703397 |
| leucemia mielógena aguda | 0.512482 |
| posibles factores | 0.501447 |
| siguientes aspectos | 0.5019 |
| leucemia aguda | 0.511873 |
| radiación quizás | 0.505162 |
| leucemia linfoblástica aguda | 0.535526 |
| LMA quizás | 0.505703 |
| hueso compacto | 0.505434 |
| neoplasias mieloides | 0.501631 |
| rayos x | 0.501258 |
| enlace drugs approved | 0.505977 |
| Acute Myeloid Leukemia | 0.506164 |
| célula madre mieloide | 0.516071 |
| cáncer.ampliar aspiración | 0.501565 |
| lÃquido cefalorraquÃdeo | 0.511938 |
|
| punción espinal.Ampliar | 0.501523 |
| National Cancer Institute | 0.501258 |
| leucemia granulocÃtica aguda | 0.512402 |
| Instituto Nacional | 0.502137 |
| célula madre linfoide | 0.510737 |
| PDQ Tratamiento | 0.503456 |
| sustancia quÃmica benceno | 0.502803 |
| leucemia mielógena | 0.513696 |
| médula espinal.ampliar quimioterapia | 0.50588 |
| leucemia mieloblástica aguda | 0.512403 |
| sistema nervioso central | 0.50789 |
| Physician Data Query | 0.504454 |
| madre mieloides | 0.518606 |
| siguientes situaciones | 0.504197 |
| células madre mieloides | 0.508803 |
| leucemia mieloide aguda | 0.995372 |
| célula madre | 0.532153 |
| blastocito mieloide | 0.505386 |
| siguientes sumarios | 0.503116 |
|
CLICK HERE |
| 1996 |
National Cancer Institute |
Html |
es |
Comunicación en la atención del cáncer (PDQ®)–Versión para pacientes |
Resumen de la información revisada por expertos acerca de la comunicación con el paciente de cáncer y sus familiares, que incluye los aspectos distintivos de la comunicación con pacientes de cáncer, los factores que afectan la comunicación y la capacitación en aptitudes para la comunicación. |
| comunicación mejora | 0.843776 |
| familia ayuda | 0.776248 |
| siguientes casos | 0.791497 |
| Physician Data Query | 0.942554 |
| mejores decisiones | 0.835028 |
| siguientes preguntas | 0.768644 |
| suministra información | 0.764377 |
| salud ayuda | 0.830465 |
| médico ayuda | 0.964949 |
|
| National Cancer Institute | 0.757167 |
| siguientes indicaciones | 0.779865 |
| ¿Cuáles archivos | 0.761738 |
| siguientes riesgos | 0.741613 |
| PDQ Comunicación | 0.825783 |
| comunicación ayuda | 0.895884 |
| Instituto Nacional | 0.809598 |
| ¿Cuáles problemas | 0.755893 |
|
CLICK HERE |
| 2106 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio. |
| PDQ Tratamiento | 0.669269 |
| general causa sÃntomas | 0.588555 |
| Visuals Online | 0.525614 |
| PDQ Exámenes | 0.596864 |
| cáncer.Los exámenes | 0.641713 |
| Physician Data Query | 0.681868 |
| pequeña cantidad | 0.54391 |
| Estados Unidos | 0.562116 |
| cuello uterino | 0.811632 |
|
| prevención revisa | 0.531482 |
| ecografÃa endovaginal | 0.56717 |
| información ayuda | 0.538498 |
| National Cancer Institute | 0.545187 |
| ecografÃa transvaginal | 0.942856 |
| siguientes riesgos | 0.532576 |
| siguientes sumarios | 0.618993 |
| Instituto Nacional | 0.58569 |
|
CLICK HERE |
| 2987 |
National Cancer Institute |
Html |
en |
Secondhand Smoke |
When you smoke, it doesn't just affect you. And it's not just irritating to those around you, it's deadly. |
| feet | 0.409991 |
| dangers | 0.420271 |
| Lung cancer | 0.428942 |
| good example | 0.428021 |
| non-smoker | 0.407426 |
| care staff | 0.426607 |
| nicotine affect | 0.427281 |
| babysitters | 0.406286 |
| body | 0.411562 |
| smoker | 0.414092 |
| children | 0.431937 |
| harms | 0.407652 |
| sure caretakers | 0.428123 |
| secondhand smoke | 0.971613 |
| non-smokers | 0.43912 |
| heart disease‚ | 0.429635 |
| Fact | 0.410452 |
| short time | 0.429909 |
| somebody | 0.406088 |
| health problems | 0.428728 |
| smokefree restaurants | 0.432863 |
| lung infections | 0.428228 |
| smoking indoors | 0.445671 |
| main way smoking | 0.477206 |
| Breathing problems | 0.428866 |
|
| indoor public places | 0.450365 |
| babies | 0.424287 |
| smokers | 0.419121 |
| air | 0.417572 |
| life | 0.412446 |
| Breathing secondhand smoke | 0.5983 |
| infant death syndrome | 0.453829 |
| smoking | 0.508887 |
| National Cancer Institute | 0.448359 |
| heart attack‚ | 0.429618 |
| kids | 0.411336 |
| quiz | 0.411311 |
| cigarette | 0.405834 |
| coughing‚ extra phlegm‚ | 0.454984 |
| bronchitis | 0.405901 |
| people | 0.432125 |
| home | 0.416331 |
| nannies | 0.405803 |
| severe attacks | 0.428972 |
| best thing | 0.428251 |
| shortness | 0.406847 |
| ear infections | 0.428442 |
| low birth weight | 0.454001 |
| family | 0.425482 |
|
CLICK HERE |
| 15641 |
National Cancer Institute |
Html |
en |
Research Performance Progress Report (RPPR) |
Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award. |
| non-competing renewal | 0.483928 |
| public access policy | 0.676757 |
| NCI program | 0.46997 |
| business official | 0.461707 |
| grants management specialist | 0.511753 |
| Institutional Review Board | 0.501375 |
| recipient accomplishments | 0.470927 |
| progress reports | 0.710572 |
| budget period | 0.703772 |
| Performance Progress Report | 0.705145 |
| competing project period | 0.527715 |
| NCBI | 0.472549 |
| NIH staff | 0.493692 |
| Type 4s | 0.462417 |
| additional information | 0.516454 |
| email notification reminders | 0.504215 |
| award progress reports | 0.597891 |
| PubMed Central ID | 0.510154 |
| budget periods | 0.468611 |
| Progress Report Additional | 0.614182 |
| multiple PIs | 0.466396 |
| contact PI | 0.464615 |
| award process | 0.523874 |
| Management staff review | 0.506533 |
| final peer-reviewed journal | 0.498525 |
|
| grants management staff | 0.612225 |
| additional information online | 0.514579 |
| recipient wishes | 0.463817 |
| different schedule | 0.465588 |
| Institutional Animal Care | 0.498988 |
| annual progress reports | 0.586399 |
| progress report | 0.93768 |
| scientific progress | 0.590143 |
| subsequent budget period | 0.638937 |
| final progress report | 0.600792 |
| NIH applications | 0.499628 |
| eRA Commons | 0.829812 |
| full-text papers | 0.492864 |
| Non-competing continuation | 0.468466 |
| NCI staff | 0.465398 |
| Streamlined Noncompeting Award | 0.520709 |
| NIH funds | 0.496167 |
| NIH Public Access | 0.629563 |
| RPPR | 0.513098 |
| NIH funding | 0.492377 |
| Research Performance Progress | 0.694309 |
| Business Technology Transfer | 0.507309 |
| incomplete applications | 0.461976 |
| Small Business | 0.499434 |
|
CLICK HERE |
| 16681 |
National Cancer Institute |
Html |
en |
Cancer Moonshot℠ Blue Ribbon Panel Members |
Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science. |
| Walton Endowed Chair | 0.567818 |
| Cancer Genome Computational | 0.597352 |
| National Cancer Advisory | 0.650925 |
| cancer advocacy groups | 0.631303 |
| Integrative Cancer Research | 0.659981 |
| Cancer Disparities Program | 0.610947 |
| C. Zamecnik Chair | 0.57469 |
| Senior Vice President | 0.528963 |
| Harvard Medical School | 0.539573 |
| Chief Executive Officer | 0.838453 |
| Moores Cancer Center | 0.633784 |
| Cancer Center | 0.989395 |
| Principal Deputy Director | 0.559096 |
| Kimmel Cancer Center | 0.636717 |
| MGH Cancer Center | 0.643509 |
| Associate Professor | 0.561481 |
| Texas MD Anderson | 0.619653 |
| Scott Cancer Center | 0.628322 |
| Hopkins University School | 0.586476 |
| Lurie Comprehensive Cancer | 0.604578 |
| National Brain Tumor | 0.535602 |
| Alumni Distinguished Professor | 0.55884 |
| cancer health disparities | 0.665713 |
| Thomas Jefferson University | 0.541957 |
| cancer prevention | 0.57231 |
|
| Lineberger Comprehensive Cancer | 0.60209 |
| Huntsman Cancer Institute | 0.643082 |
| Ph.D | 0.602332 |
| Anderson Cancer Center | 0.720144 |
| Dana-Farber Cancer Institute | 0.630726 |
| Louisiana State University | 0.545794 |
| Pfizer Worldwide Research | 0.555824 |
| National Cancer Institute | 0.714187 |
| Cancer Research | 0.712054 |
| Sidney Kimmel | 0.530896 |
| Hospital Cancer Center | 0.648303 |
| Blue Ribbon Panel | 0.726957 |
| M.D | 0.540388 |
| Executive Vice President | 0.545293 |
| MD Anderson Cancer | 0.692003 |
| Ludwig Cancer Research | 0.634757 |
| Clinical Cancer Care | 0.584227 |
| Comprehensive Cancer Center | 0.832766 |
| Clausen Distinguished Professor | 0.578861 |
| Cancer Survivorship | 0.543835 |
| Kimmel Comprehensive Cancer | 0.643464 |
| Vanderbilt-Ingram Cancer Center | 0.63051 |
| University Feinberg School | 0.566744 |
| Deputy Director | 0.630447 |
|
CLICK HERE |
| 16775 |
National Cancer Institute |
Html |
es |
Cancell/Cantron/Protocel (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de Cancell/Entelev como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.429084 |
| New Hampshire Avenue | 0.419912 |
| cabo ensayos | 0.419001 |
| Drug Administration | 0.412413 |
| NCI Best Case | 0.439351 |
| tipo cancell | 0.440349 |
| mejores pruebas | 0.415762 |
| datos bibliográficos pubmed | 0.42161 |
| siguientes preguntas | 0.412513 |
| James V | 0.418429 |
| National Cancer Institute | 0.425345 |
| siguientes riesgos | 0.416342 |
| seguro médico | 0.411884 |
| Instituto Nacional | 0.685274 |
| vitamina e | 0.418575 |
| Salud Complementaria | 0.444832 |
|
| Visuals Online | 0.415001 |
| complementarias revisa | 0.421711 |
| Physician Data Query | 0.488672 |
| nombre cancell | 0.440323 |
| Estados Unidos | 0.994944 |
| libre uso | 0.416016 |
| suficiente actividad | 0.418205 |
| siguientes sustancias | 0.422749 |
| página manejo | 0.413947 |
| ¿El tratamiento | 0.424367 |
| ¿Los beneficios | 0.412704 |
| juntos cam | 0.411781 |
| Series Program | 0.412549 |
| medicina complementaria | 0.882014 |
| Institutos Nacionales | 0.47694 |
|
CLICK HERE |
| 16826 |
National Cancer Institute |
Html |
en |
Early Onset Malignancies Initiative |
The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations. |
| community sites | 0.48513 |
| control group | 0.496806 |
| certain minority populations | 0.77365 |
| exome sequencing | 0.513318 |
| ethnic populations | 0.59564 |
| ethnic groups | 0.477288 |
| multiple platforms | 0.483426 |
| early detection | 0.483135 |
| tumor behavior | 0.507221 |
| cutting-edge genomic characterization | 0.794697 |
| early age | 0.515521 |
| genomic datasets | 0.554094 |
| patient populations | 0.708455 |
| multiple myeloma | 0.479782 |
| critical research | 0.469762 |
| rich genomic data | 0.741156 |
| cancer types | 0.666255 |
| Thorough clinical data | 0.657553 |
| extensive data | 0.513023 |
| clinical measures | 0.479008 |
| molecular targets | 0.47719 |
| TCGA | 0.415616 |
| tumor progression | 0.525349 |
| earlier age | 0.508182 |
|
| higher rates | 0.504515 |
| important insights | 0.491579 |
| molecular drivers | 0.46961 |
| cancer type | 0.492461 |
| NCI Genome Characterization | 0.808398 |
| early disease | 0.497354 |
| clinical updates | 0.489197 |
| disease monitoring | 0.476658 |
| Genome Characterization Pipeline | 0.932301 |
| collaborative initiative | 0.505734 |
| NCI genomic characterization | 0.824673 |
| EOMI | 0.680345 |
| NCI Community Oncology | 0.754977 |
| total RNA sequencing | 0.668278 |
| underrepresented minorities | 0.53639 |
| Cancer Genome Atlas | 0.669216 |
| tissue samples | 0.659999 |
| Early Onset Malignancies | 0.747146 |
| EOMI data | 0.528397 |
| treatment response | 0.492799 |
| cancer risk | 0.496991 |
| genome sequencing | 0.549082 |
| Cancer Prevention | 0.5334 |
| normal tissue samples | 0.654735 |
|
CLICK HERE |